TMDX

TMDX's PAD Aviation investment expands its OCS model into Europe, aiming to boost organ logistics, utilization and adoption.

Strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe ANDOVER, Mass., July 6, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the closing of its strategic investment in PAD Aviation, a premier Germany-based private aviation operator.

Investing in attractive stocks on the dip is a great way to earn above-average returns over the long run. The three stocks below have faced some challenges, but their prospects look fairly strong.

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

TransMedics (TMDX) faces decelerating revenue growth, margin pressure, and increased investment, yet maintains strong market share gains and competitive positioning. TMDX's logistics and clinical services now comprise nearly 40% of revenue, enhancing competitive advantages and supporting long-term margin strength. Despite growth normalizing to 20-25% and compressed margins, I see current valuation at 4x EV/Sales as attractive, supporting a Buy rating.

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

TransMedics remains a 'Strong Buy' despite a 50% stock decline and Q1 2026 earnings miss, supported by robust long-term growth initiatives. TMDX's portfolio expansion includes CHOPS as a complementary offering and aggressive European NOP rollout, aiming to expand its addressable market. Q1 2026 revenue grew 21% year-over-year to $174 million, led by liver segment strength, though higher costs compressed margins and net income.

ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 19, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 37,367 shares of its common stock and an aggregate of 24,848 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics.

ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026.